ANAVEX LIFE SCIENCES CORP (AVXL) Stock Price, Quote, News and Overview
NASDAQ:AVXL - Nasdaq - US0327973006 - Common Stock - Currency: USD
AVXL Quote, Performance and Key Statistics
8.35
-0.33 (-3.8%)
The current stock price of AVXL is 8.35 USD. In the past month the price decreased by -18.14%. In the past year, price increased by 69.72%.
AVXL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AVXL
Company Profile
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 40 full-time employees. The company went IPO on 2006-04-13. The firm is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The firm analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.
Company Info
ANAVEX LIFE SCIENCES CORP
630 5Th Avenue, 20Th Floor
New York City NEW YORK 10019 US
CEO: Christopher Missling
Employees: 40
Company Website: https://www.anavex.com
Investor Relations: http://www.anavex.com/investors
Phone: 18446893939
ANAVEX LIFE SCIENCES CORP / AVXL FAQ
What is the stock price of ANAVEX LIFE SCIENCES CORP today?
The current stock price of AVXL is 8.35 USD. The price decreased by -3.8% in the last trading session.
What is the ticker symbol for ANAVEX LIFE SCIENCES CORP stock?
The exchange symbol of ANAVEX LIFE SCIENCES CORP is AVXL and it is listed on the Nasdaq exchange.
On which exchange is AVXL stock listed?
AVXL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANAVEX LIFE SCIENCES CORP stock?
9 analysts have analysed AVXL and the average price target is 36.69 USD. This implies a price increase of 339.43% is expected in the next year compared to the current price of 8.35. Check the ANAVEX LIFE SCIENCES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANAVEX LIFE SCIENCES CORP worth?
ANAVEX LIFE SCIENCES CORP (AVXL) has a market capitalization of 708.25M USD. This makes AVXL a Small Cap stock.
How many employees does ANAVEX LIFE SCIENCES CORP have?
ANAVEX LIFE SCIENCES CORP (AVXL) currently has 40 employees.
What are the support and resistance levels for ANAVEX LIFE SCIENCES CORP (AVXL) stock?
ANAVEX LIFE SCIENCES CORP (AVXL) has a support level at 8.34 and a resistance level at 8.39. Check the full technical report for a detailed analysis of AVXL support and resistance levels.
Should I buy ANAVEX LIFE SCIENCES CORP (AVXL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AVXL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AVXL, evaluating the profitability, health, valuation and growth aspects
- ANAVEX LIFE SCIENCES CORP (AVXL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANAVEX LIFE SCIENCES CORP (AVXL) Sales and EPS estimates to see what analysts future expectations are.
- ANAVEX LIFE SCIENCES CORP (AVXL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANAVEX LIFE SCIENCES CORP (AVXL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANAVEX LIFE SCIENCES CORP (AVXL) Stock Chart to make your own analysis
- ANAVEX LIFE SCIENCES CORP (AVXL) Latest news and press-releases to stay up to date.
Does ANAVEX LIFE SCIENCES CORP (AVXL) stock pay dividends?
AVXL does not pay a dividend.
When does ANAVEX LIFE SCIENCES CORP (AVXL) report earnings?
ANAVEX LIFE SCIENCES CORP (AVXL) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of ANAVEX LIFE SCIENCES CORP (AVXL)?
ANAVEX LIFE SCIENCES CORP (AVXL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.55).
What is the Short Interest ratio of ANAVEX LIFE SCIENCES CORP (AVXL) stock?
The outstanding short interest for ANAVEX LIFE SCIENCES CORP (AVXL) is 28.4% of its float. Check the ownership tab for more information on the AVXL short interest.
AVXL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to AVXL. When comparing the yearly performance of all stocks, AVXL is one of the better performing stocks in the market, outperforming 90.38% of all stocks.
AVXL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVXL. While AVXL has a great health rating, there are worries on its profitability.
AVXL Financial Highlights
Over the last trailing twelve months AVXL reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -1.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.48% | ||
| ROE | -41.92% | ||
| Debt/Equity | 0 |
AVXL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to AVXL. The Buy consensus is the average rating of analysts ratings from 9 analysts.